Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Bibliographic Details
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000856
_version_ 1797279723935498240
collection DOAJ
first_indexed 2024-03-07T16:31:10Z
format Article
id doaj.art-0475c097a3044ac8b85379d7cb898798
institution Directory Open Access Journal
issn 2572-9241
language English
last_indexed 2024-03-07T16:31:10Z
publishDate 2023-03-01
publisher Wiley
record_format Article
series HemaSphere
spelling doaj.art-0475c097a3044ac8b85379d7cb8987982024-03-03T10:39:05ZengWileyHemaSphere2572-92412023-03-0173e85610.1097/HS9.0000000000000856202303000-00010Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myelomahttp://journals.lww.com/10.1097/HS9.0000000000000856
spellingShingle Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
HemaSphere
title Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
title_full Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
title_fullStr Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
title_full_unstemmed Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
title_short Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
title_sort correction notice carfilzomib pomalidomide and dexamethasone as second line therapy for lenalidomide refractory multiple myeloma
url http://journals.lww.com/10.1097/HS9.0000000000000856